What is William Blair's Forecast for SLN Q3 Earnings?

Key Points

• William Blair has revised its Q3 2025 earnings per share (EPS) estimate for Silence Therapeutics PLC from ($0.38) to ($0.39), indicating a continued negative outlook for the company's financial performance.
• The firm's most recent earnings report showed Silence Therapeutics missed consensus estimates with a reported EPS of ($0.54) for the quarter, against an expected ($0.27).
• Despite the pessimistic forecast, the current consensus rating for Silence Therapeutics is a "Moderate Buy", with an average target price of $33.83, according to MarketBeat.com.

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Free Report) - Research analysts at William Blair cut their Q3 2025 EPS estimates for shares of Silence Therapeutics in a note issued to investors on Thursday, August 7th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.39) for the quarter, down from their prior forecast of ($0.38). The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics' Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.91) EPS.

SLN has been the topic of a number of other research reports. The Goldman Sachs Group cut their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Friday, May 9th. Morgan Stanley dropped their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Wall Street Zen downgraded shares of Silence Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. Chardan Capital reiterated a "buy" rating and issued a $35.00 target price on shares of Silence Therapeutics in a report on Friday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, June 13th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Stock Up 3.4%

Shares of Silence Therapeutics stock traded up $0.19 during midday trading on Monday, reaching $5.78. 86,861 shares of the company's stock traded hands, compared to its average volume of 209,951. The company's 50 day simple moving average is $5.80 and its 200 day simple moving average is $4.70. Silence Therapeutics has a 52 week low of $1.97 and a 52 week high of $20.48.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.27). The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $8.50 million. Silence Therapeutics had a negative net margin of 294.20% and a negative return on equity of 67.48%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Redmile Group LLC boosted its position in shares of Silence Therapeutics by 26.3% during the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock valued at $16,507,000 after acquiring an additional 500,000 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Silence Therapeutics by 424.8% in the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after buying an additional 849,676 shares in the last quarter. Point72 Asset Management L.P. boosted its position in Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock valued at $4,356,000 after buying an additional 165,300 shares in the last quarter. Cantor Fitzgerald L. P. boosted its position in Silence Therapeutics by 61.5% in the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company's stock valued at $3,713,000 after buying an additional 205,534 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Silence Therapeutics by 48,165.6% in the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock valued at $3,434,000 after buying an additional 498,032 shares in the last quarter. Institutional investors own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.